Korea considers letting third parties independently inspect GMP compliance for Class II devices
This article was originally published in SRA
South Korea has proposed several changes to its current good manufacturing practice requirements for medical devices, including allowing third party institutions to independently inspect Class II products so that government authorities may focus their inspection resources on high-risk devices1.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.